Drug Patent Watch
MARCH 16, 2022
Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from one supplier. There are seven patents…. The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MARCH 18, 2022
Today’s guest post comes from Ashwin Mundra, Chief Revenue Officer at Kalderos. As Ashwin explains, manufacturers face a gap between visible, non-compliant drug discounts and the actual level of non-compliant discounts. He describe Kalderos’ technology-enabled, machine learning-based methods for identifying drug discount non-compliance. To learn more, register to receive a copy of Kalderos’ annual report, available April 13, 2022: Conquering the “Great Unknown”: Connecting the data gaps that kee
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 18, 2022
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab 1. In RELATIVITY-047, Opdualag more than doubled median progression-free survival compared to nivolumab monotherapy, an established standard of care 1,2. Relatlimab is the third immune checkpoint inhibitor from Bristol Myers Squibb, adding to the Company’s growing and differentiated oncology portfolio.
The Strateos Blog: Drug Discovery
MARCH 18, 2022
Strateos had the pleasure of participating at the PharmaIQ Live: Smartlab Digital 2022 conference held between March 8-9th, which focused on the potential of Lab 4.0 strategies to increase the speed, efficiency and reduce the cost of the drug discovery process. John Harman, Sr. Director of Product Management at Strateos, with over 30 years of small molecule drug discovery experience, gave a talk where he outlined key industry pain points and how cloud labs can provide solutions by increasing con
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
MARCH 18, 2022
Annual Drug Patent Expirations for DEFINITY Definity is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are five patents…. The post New patent for Lantheus Medcl drug DEFINITY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
MARCH 15, 2022
I am pleased to announce our new 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Click here to download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study Examines Consolidation and Vertical Integration of U.S.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Tecan
MARCH 17, 2022
By Dajana Domik Neopterin is a broad range inflammation marker which can be measured in the blood of patients and indicates a multitude of diseases from acute viral infections to autoimmune conditions. 1 This marker can serve as an essential “catch all” as neopterin levels are elevated due to any viral or bacterial invasion, which indicates an infection within the body without the need of several specific tests to confirm.
Drug Patent Watch
MARCH 18, 2022
Annual Drug Patent Expirations for DEFINITY+RT Definity Rt is a drug marketed by Lantheus Medcl and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Lantheus Medcl drug DEFINITY RT appeared first on DrugPatentWatch - Make Better Decisions.
EG Life Sciences
MARCH 16, 2022
Many of you reading this blog have asked yourselves, "What does the future in biotech and pharma look like?" When I started thinking about the answer to this question, I remembered the Dick Tracy comic strip in which the hero wore an electronic gadget on his wrist, a 2-way wrist radio. Apple came out with their invention of the Apple Watch as the first smart watch on April 24, 2015, wowing consumers everywhere.
The Pharma Data
MARCH 18, 2022
Columbia Engineering researchers report that they have developed a “cloaking” system that temporarily hides therapeutic bacteria from immune systems, enabling them to more effectively deliver drugs to tumors and kill cancer cells in mice. By manipulating the microbes’ DNA, they programmed gene circuits that control the bacteria surface, building a molecular “cloak” that encapsulates the bacteria. “What’s really exciting about this work is that we are able to d
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Creative Biolabs
MARCH 15, 2022
Multiple myeloma is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, in a recent study published in Science Translational Medicine entitled “Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain”, scientists have discovered the CD98 heavy chain, a common component of amino acid transporters, may represent a promising monoclonal antibody for the treatment of multiple myeloma.
Drug Patent Watch
MARCH 18, 2022
Annual Drug Patent Expirations for OXLUMO Oxlumo is a drug marketed by Alnylam Pharms Inc and is included in one NDA. There are eleven patents protecting this drug. This drug…. The post New patent for Alnylam Pharms drug OXLUMO appeared first on DrugPatentWatch - Make Better Decisions.
ProRelix Research
MARCH 15, 2022
Clinical trials are research studies in which participants volunteer to test new treatments, therapies, or tests in the hopes of preventing, detecting, treating, or managing a wide range of diseases […]. The post Advantages of Conducting Clinical Trials in Australia appeared first on ProRelix Research.
The Pharma Data
MARCH 17, 2022
Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo District Court.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Channels
MARCH 14, 2022
Asembia’s Specialty Pharmacy Summit 2022. May 2 – 5, 2022 | Las Vegas www.asembiasummit.com. Asembia's Specialty Pharmacy Summit 2022 is back! This is a must-attend event for anyone connected to specialty pharmacy. You'll meet an impressive diversity of people from pharmacies, manufacturers, health plans, wholesalers, hospital systems, pharmacy benefit managers, patient advocacy groups, and more.
Drug Patent Watch
MARCH 17, 2022
This chart shows the drugs with the most patents in Colombia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Colombia? appeared first on DrugPatentWatch - Make Better Decisions.
Drug & Device Law
MARCH 14, 2022
This post is from the non-Dechert side of the blog. From the first time that we discussed Lexecon, Inc. v. Milberg Weiss Bershad Hynes & Lerach , 523 U.S. 26 (1998), and the related MDL concept of Lexecon waivers, we’ve been plenty leery of defendants in cases transferred into multidistrict litigation waiving their retransfer rights under Lexecon and exposing their cases to the “MDL treatment” in bellwether trials.
The Pharma Data
MARCH 17, 2022
The Better Life Farming Alliance (BLF) supports smallholder farmers to improve their livelihoods / Bayer is a part of the BLF global alliance along with the International Finance Corporation (IFC) – a member of the World Bank Group –, Netafim – a global irrigation specialist, and more than 30 local partners / Opening of first BLF Center in Mexico. The Better Life Farming (BLF) Alliance has been launched in Latin America starting with the opening of the first BLF Center in Córdoba, Mexico in Febr
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
The Pharma Data
MARCH 16, 2022
ADUHELM continued to reduce two key Alzheimer’s disease pathologies, amyloid beta plaques and p-tau181, in patients treated for up to two and a half years Data from both Phase 3 studies also show that clinical decline was reduced in participants who had plasma p-tau181 reduction at 78 weeks These data further inform the scientific evidence for amyloid as a surrogate biomarker and the importance of continuation of treatment.
The Pharma Data
MARCH 16, 2022
Biogen Inc. (Nasdaq: BIIB) announced that The Journal of Prevention of Alzheimer’s Disease (JPAD) today published a peer-reviewed manuscript detailing data from the pivotal Phase 3 EMERGE and ENGAGE trials for ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer’s disease. The publication includes results from the primary, secondary and tertiary endpoints in the trials, as well as safety data and biomarker sub-studies.
The Pharma Data
MARCH 16, 2022
Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta The World Health Organization (WHO) has recently reported that the BA.2 subvariant is steadily increasing in prevalence, specifically in Denmark Use of these tests assess the spread of circulating variants and can help monitor the potential impact of therapeutics, vaccines and public health interventions All R
The Pharma Data
MARCH 16, 2022
The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessment EMPA-KIDNEY is the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease to date Detailed results are expected to be presented later this year. The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independe
The Pharma Data
MARCH 16, 2022
The Director of the Chemical Biology Department at the Max Planck Institute for Medical Research in Heidelberg receives the award in recognition of his ground-breaking work / Four young scientists are presented with the Early Excellence in Science Award / Werner Baumann: “Breakthrough innovation at the intersection of biology, chemistry and artificial intelligence”.
The Pharma Data
MARCH 16, 2022
Entries for 3rd edition in 2022 takes total of short films received to nearly 3500 since the initiative launched in 2020. More than 1000 film makers from over 110 countries have submitted short films for the 3rd edition of the WHO Health for All Film Festival (HAFF), on themes ranging from the trauma of war to living with COVID-19. Some 70 films have been chosen for the shortlist, which will be reviewed by international actors and development leaders, before the announcement of the winners in mi
Drug Patent Watch
MARCH 16, 2022
Annual Drug Patent Expirations for VIMPAT Vimpat is a drug marketed by Ucb Inc and is included in three NDAs. It is available from three suppliers. There is one patent…. The post New patent expiration for Ucb Inc drug VIMPAT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 16, 2022
This chart shows the pharmaceutical companies with the most patents in Poland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Poland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 16, 2022
Annual Drug Patent Expirations for ICLUSIG Iclusig is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Takeda Pharms drug ICLUSIG appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
MARCH 16, 2022
Annual Drug Patent Expirations for XYWAV Xywav is a drug marketed by Jazz and is included in one NDA. It is available from one supplier. There are eleven patents protecting…. The post New patent for JAZZ drug XYWAV appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
MARCH 15, 2022
Teva is donating medicines valued at over $11M, for acute therapies in support of Ukrainian refugees The donations include over 1 million packages of antibiotics and other essential medicines as well as hygienic products for Ukrainian infants and children. Teva Pharmaceutical Industries Ltd. today announced a donation of essential medical products valued at over $11M, for acute therapies in humanitarian support of Ukrainian refugees.
The Pharma Data
MARCH 15, 2022
Demerger and listing of Haleon expected in July 2022. GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) today announced the appointment of six directors to the designate Board of Haleon, the new independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022. Haleon will be a new global-leading company in Consumer Health, and is strongly positioned to deliver better everyday health, sustainable above-market growth and attractive returns to sharehold
The Pharma Data
MARCH 15, 2022
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). The sBLA submitted to the FDA by AstraZeneca included data from the OSTRO Phase III trial, which met both co-primary endpoints with a safety profile consistent with the known profile of the medicine. 1 The CRL requested additional
The Pharma Data
MARCH 15, 2022
AMEERA-3 trial did not meet primary endpoint of improving progression-free survival Ongoing trials continue as planned, including AMEERA-5 and AMEERA-6. The Phase 2 AMEERA-3 clinical trial evaluating amcenestrant, an investigational optimized oral selective estrogen receptor degrader (SERD), did not meet its primary endpoint of improving progression-free survival (PFS) as assessed by an independent central review.
The Pharma Data
MARCH 15, 2022
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo monotherapy as a first-line treatment for previously untreated unresectable or metastatic melanoma.
Expert insights. Personalized for you.
85 
Let's personalize your content